The rate of epidermal cell proliferation was analyzed in a lesion and in normal skin area of a female patient of 21 suffering from erythrokeratodermia congenitalis progressiva symmetrica (Gottron). The study was based on incorporation of labelled thymidine in epidermal cells followed by radioautography. Mitotic and labelling indices were counted and duration of different phases of cell cycle (S, G2, M and G1 were calculated. In the uninvolved skin, the mitotic index was 0.3%, labelling index 4.0%, S phase 7.2 h, median G2 phase 3.5 h and mitosis 32 min (late prophase to anaphase). G1 phase was 169 h and the germinative cell cycle 180 h. In the lesion, mitotic index was 1.0%, labelling index 11.6%, S phase 8.8 h, median G2 phase 3.7 h, mitosis 46 min, G1 phase was 66 h and the germinative cell cycle 76 h. It was concluded that the rate of cell proliferation is markedly increased in the lesion because of shortening of the interphase. The mode of hyperkeratosis was considered to be due to increased cell proliferation rather than to retention of the horny layer.

This content is only available via PDF.
© 1971 S. Karger AG, Basel
1971
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.